Product Description
a useful sedative neuroleptic drug in troublesome chronic psychotic patients (Sourced from: https://pubmed.ncbi.nlm.nih.gov/906888/)
Mechanisms of Action: 5-HT2 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Belgium | Denmark | France | Germany | Greece | Italy | Luxembourg | Netherlands | Switzerland | Tunisia
Approved Indications: None
Known Adverse Events: None
Company: PharmaNeuroBoost
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Intellectual Disability
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2016-002859-19 | P3 |
Active, not recruiting |
Intellectual Disability |
2018-05-22 |